Platelet aggregation targets

Platelet aggregation targets encompass a diverse group of proteins and enzymes that regulate the activation and clumping of platelets, a process essential for hemostasis but also central to pathological thrombosis [ahajournals.org, 2015]. Key targets include the P2Y12 receptor, which mediates ADP-induced activation; Cyclooxygenase-1 (COX-1), which produces the pro-aggregatory mediator thromboxane A2; and the Glycoprotein IIb/IIIa (integrin αIIbβ3) receptor, which serves as the final common pathway for platelet-platelet bridging via fibrinogen [nih.gov, 2024]. Other significant targets include the protease-activated receptor 1 (PAR-1) for thrombin and the collagen receptor GPVI [nih.gov, 2024]. Drugs targeting these molecules, such as clopidogrel, aspirin, and abciximab, are cornerstones in the management of cardiovascular diseases like myocardial infarction and stroke [nih.gov, 2024]. While highly effective at preventing ischemic events, these therapies carry a significant risk of bleeding due to the systemic inhibition of normal clotting mechanisms [clinpgx.org, 2024].

Other names

Antiplatelet targetsPlatelet receptorsThrombotic targetsPlatelet activation targets

Cyclooxygenase-1 inhibition, P2Y12 receptor antagonism, Glycoprotein IIb/IIIa inhibition, and Protease-activated receptor 1 (PAR-1) antagonism.